Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice : Episode 10

Advanced NSCLC: Interpreting Data From the POSEIDON Trial

May 26, 2023

Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care
Kristen A. Marrone, MD, Johns Hopkins Medicine

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

EP: 1.Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer

EP: 2.Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies

EP: 3.What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?

EP: 4.Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer

EP: 5.Considerations for Incorporating Perioperative Treatment in Resectable NSCLC

EP: 6.Factors in Selecting IO Therapy for Patients With Advanced NSCLC

EP: 7.Selecting Therapy for Advanced NSCLC Based on PDL1 and NGS Testing

EP: 8.Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer

EP: 9.Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations

EP: 10.Advanced NSCLC: Interpreting Data From the POSEIDON Trial

Related Videos

Henry S. Park, MD, MPH

Expert on lung cancer

Anne Chiang, MD, PhD

Sarah Goldberg, MD, MPH

Experts on prostate cancer

Experts on prostate cancer

Ferdinandos Skoulidis, MD, PhD, MRCP

Experts on DTC

Related Content

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Clinical Updates for the Management of Lung Cancer Brain Metastases

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Clinical Updates for the Management of Lung Cancer Brain Metastases

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Clinical Updates for the Management of Lung Cancer Brain Metastases

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

Related Content

Abderrahim Oukessou, MD

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

Jorge M. Mercado, MD; Stephen Kovacs, DO

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Lilyana Angelov, MD

Clinical Updates for the Management of Lung Cancer Brain Metastases

Luis E. Raez, MD, FACP, FCCP

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

John V. Heymach, MD

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

FDA

FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

Latest Conference Coverage

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.